GTC
AKTX

Ghost Tree Capital’s Akari Therapeutics AKTX Stock Holding History

Ghost Tree Capital’s Portfolio AKTX Stock Details AKTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q2 		– Sell
-58
Closed -$516K – 69
2017
Q1 		$516K Hold
58
– – 0.1% 64
2016
Q4 		$328K Hold
58
– – 0.08% 70
2016
Q3 		$397K Hold
58
– – 0.06% 85
2016
Q2 		$629K Hold
58
– – 0.18% 57
2016
Q1 		$653K Sell
58
-1
-2% -$10.4K 0.37% 46
2015
Q4 		$683K Buy
59
+34
+136% +$505K 0.28% 45
2015
Q3 		$488K Buy
+25
New +$296K 0.22% 65

Other funds holding AKTX

DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
VMI
VHCP Management II New York $379M AUM 421.62% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
QF
QVT Financial New York $1.37B AUM 148.1% 1-Year Est. Return
HP
Hikari Power Tokyo, Japan $855M AUM 14.24% 1-Year Est. Return
VKH
Virtu KCG Holdings New York $3.6B AUM 19.31% 1-Year Est. Return
Bank of Montreal
Bank of Montreal Toronto, Ontario, Canada $269B AUM 31.4% 1-Year Est. Return

Ghost Tree Capital's AKTX Position: Q2 2017 in Review

Ghost Tree Capital sold out of Akari Therapeutics (AKTX) in Q2 2017, closing a stake of 58 shares — an estimated $516K sold.

Ghost Tree Capital first reported a position in AKTX in Q3 2015 and held it in 7 quarters. The position peaked at $683K in Q4 2015. 14 funds tracked by Wall St. Rank hold AKTX as of Q2 2017.

  • Ghost Tree Capital reported no remaining Akari Therapeutics position as of Q2 2017 after selling out during the quarter.
  • Ghost Tree Capital sold 58 Akari Therapeutics shares in Q2 2017, an estimated $516K.
  • Ghost Tree Capital first reported a position in Akari Therapeutics in Q3 2015 and held it in 7 quarters.
  • Ghost Tree Capital's Akari Therapeutics position peaked at $683K in Q4 2015.
  • 14 funds tracked by Wall St. Rank held Akari Therapeutics as of Q2 2017.

Based on Ghost Tree Capital's 13F filing for Q2 2017, filed 14 Aug 2017.